Aileron Therapeutics, Inc. (NASDAQ: ALRN) was founded in 2001, formerly known as Renegade Therapeutics, Inc., changed to its current name in February 2007, headquartered in Cambridge, Massachusetts, USA, with 23 full-time employees. It is a clinical stage biopharmaceutical company that develops and commercializes a new class of therapeutic drugs in the United States.
Aileron Therapeutics (ALRN):
Aileron Therapeutics, Inc.’s main product candidate is ALRN-6924, a stapled peptide, which is a peptide with a synthetic scaffold (“nail”). A peptide with multiple tandem staples is sometimes called a suture peptide. Peptide binding is used to enhance the pharmacological properties of peptides.) Currently in the phase I clinical trials for the treatment of advanced solid tumors or lymphomas; in the phase IIa clinical trials for the treatment of peripheral T-cell lymphoma; in the treatment of acute myelogenous leukemia (AML) ) And advanced myelodysplastic syndrome (MDS) phase I clinical trials; in the phase II trial phase of combination with cytosine arabinoside (cytosine arabinoside) for the treatment of AML/MDS.
In addition, Aileron Therapeutics, Inc. is also developing the next generation of wild-type p53 reactivators, currently in the preclinical stage for the treatment of solid and liquid tumors.
Aileron Therapeutics (ALRN) investment:
Aileron Therapeutics, Inc. (NASDAQ: ALRN) was listed on Nasdaq on 6/29/2017 IPO, with an issue price of US$15, and 3.75 million shares were issued, which raised US$56.25 million. The stock code is ALRN. On the first day of listing, the company broke -28%.